List of Excipients in Branded Drug TEMODAR

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme LLC	TEMODAR	temozolomide	0085-3004	ALCOHOL
Merck Sharp & Dohme LLC	TEMODAR	temozolomide	0085-3004	AMMONIA
Merck Sharp & Dohme LLC	TEMODAR	temozolomide	0085-3004	ANHYDROUS LACTOSE
Merck Sharp & Dohme LLC	TEMODAR	temozolomide	0085-3004	BUTYL ALCOHOL
Merck Sharp & Dohme LLC	TEMODAR	temozolomide	0085-3004	FD&C BLUE NO. 2
Merck Sharp & Dohme LLC	TEMODAR	temozolomide	0085-3004	FERRIC OXIDE RED
Merck Sharp & Dohme LLC	TEMODAR	temozolomide	0085-3004	FERRIC OXIDE YELLOW

Temodar Excipient Strategy and Commercial Opportunities for Temozolomide

Last updated: August 25, 2026

Temodar is the branded formulation of temozolomide, an oral alkylating agent marketed by Merck for glioblastoma and anaplastic astrocytoma. Its core commercial opportunity is no longer protection of the active ingredient. It is formulation differentiation: stable oral dosage forms, patient-friendly administration, hospital-ready intravenous products, and specialty excipient systems that support generic substitution, compounding, and global distribution.

Temozolomide has a relatively simple capsule formulation, but the molecule is sensitive to hydrolysis in aqueous and alkaline environments. Excipient selection must preserve dissolution, content uniformity, chemical stability, and bioequivalence. Commercially attractive opportunities include lactose-free capsules, improved capsule shells, oral liquid or dispersible products, ready-to-use intravenous presentations, and manufacturing platforms that reduce occupational exposure to a cytotoxic compound.

What excipients are used in Temodar capsules?

Temodar capsules contain temozolomide with a relatively limited excipient system designed for rapid oral release and acceptable stability.

Documented capsule excipients

The U.S. prescribing information identifies the following inactive ingredients for Temodar capsules:

Component	Function
Anhydrous lactose	Diluent and capsule-fill carrier
Colloidal silicon dioxide	Glidant and flow aid
Sodium starch glycolate	Disintegrant
Tartaric acid	Acidifying agent and stability-supporting excipient
Gelatin	Hard capsule shell
Titanium dioxide	Opacifier and colorant
Sodium lauryl sulfate	Wetting agent
Pharmaceutical colorants	Strength-specific capsule identification

Temodar is supplied in 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, and 250 mg capsules. Strength differentiation uses capsule colors and markings, reducing dispensing errors in a regimen that commonly involves daily dosing during radiation therapy and repeated treatment cycles afterward. [1]

The presence of tartaric acid is technically important. Temozolomide is more stable under acidic conditions than at neutral or alkaline pH. An acidifying excipient can help limit degradation during manufacturing and storage, although the finished product must still meet dissolution and impurity specifications.

Why the Temodar excipient system is commercially relevant

The capsule formulation uses conventional excipients, so generic manufacturers do not need to replicate every inactive ingredient. An ANDA applicant generally can use a different formulation if the product satisfies pharmaceutical equivalence, bioequivalence, quality, and labeling requirements.

The commercial constraints are practical:

• Lactose may exclude patients with severe lactose intolerance or create procurement issues for lactose-free hospital formularies.
• Sodium lauryl sulfate can create compatibility and tolerability concerns in some formulation programs.
• Gelatin limits suitability for certain vegetarian, religious, or animal-origin policies.
• Cytotoxic powder handling requires containment during blending, encapsulation, cleaning, and quality control.
• Multiple capsule strengths increase inventory and packaging complexity.
• Temozolomide degradation can affect shelf life, impurity profiles, and dissolution performance.

An excipient strategy that solves one of these problems may support a differentiated generic or specialty product even when the active-ingredient patent estate is no longer commercially blocking.

How does temozolomide chemistry affect excipient selection?

Temozolomide is a prodrug that undergoes conversion to the active alkylating species at physiological pH. The same chemistry creates a formulation challenge: aqueous and higher-pH environments can accelerate degradation.

Key formulation requirements

A temozolomide oral formulation should prioritize:

1. Low water activity during manufacturing and storage.
2. An acidic microenvironment where chemically justified.
3. Rapid and reproducible disintegration.
4. Minimal interaction with moisture-sensitive packaging.
5. Controlled exposure of operators to cytotoxic powder.
6. Consistent dissolution across capsule strengths.

The existing combination of anhydrous lactose, tartaric acid, sodium starch glycolate, silica, and a wetting agent is consistent with a dry, immediate-release formulation. A reformulation that increases hygroscopicity, delays disintegration, or shifts the microenvironmental pH could create a bioequivalence or stability problem.

Excipient compatibility priorities

Formulation issue	Relevant excipient or process response
Moisture-driven degradation	Low-moisture excipients, controlled humidity, high-barrier packaging
Poor powder flow	Colloidal silicon dioxide, engineered particle size, contained transfer
Slow disintegration	Sodium starch glycolate or alternative superdisintegrant
Variable wetting	Surfactant selection and controlled granulation
Capsule brittleness	Shell moisture control and packaging optimization
Acid-base instability	Tartaric acid or another qualified acidifying system
Cytotoxic exposure	Closed handling, isolator processing, and dust containment

A direct-compression platform may reduce processing steps, but flow, blend uniformity, and occupational containment must be demonstrated. Wet granulation can improve uniformity but introduces water and drying variables that may increase degradation risk.

What formulations are protected by Temodar patents?

Temozolomide’s original active-ingredient patent protection has expired in the United States and major markets. The commercial market is therefore open to generic oral and intravenous products, subject to applicable regulatory requirements and any jurisdiction-specific rights.

The principal historical U.S. patent associated with temozolomide is U.S. Patent No. 5,260,291, covering the compound and related pharmaceutical use. The patent was filed in the early 1990s and has expired. Temozolomide was approved in the United States in 1999, while the injectable formulation received later approval. [2,3]

Current patent and exclusivity position

Protection category	Commercial position
Temozolomide active ingredient	Historical protection expired
Original oral capsule formulation	No longer a practical U.S. market barrier
Intravenous temozolomide	Generic competition is possible subject to approval
Method-of-use patents	Any remaining rights must be assessed claim by claim and jurisdiction by jurisdiction
Orange Book listed patents	Current FDA records control; historical patents should not be treated as active without verification
Regulatory exclusivity	Original approval exclusivity has expired
Biosimilar exclusivity	Not applicable because temozolomide is a synthetic small molecule

The relevant intellectual-property opportunity is not ownership of the Temodar formulation itself. It is development of a new, patentable delivery or manufacturing system. Potential claim categories include:

• A stable temozolomide suspension with defined pH and impurity limits.
• A moisture-protective capsule or blister configuration.
• A dispersible or orally disintegrating tablet with rapid release.
• A ready-to-administer intravenous solution or reconstituted product.
• A closed manufacturing process for cytotoxic powder.
• A low-dust multiparticulate dosage form.
• A pediatric dosage form with acceptable taste and dose flexibility.
• A co-packaged administration system that reduces handling risk.

A patent based solely on replacing one conventional diluent with another would face a high obviousness risk. Stronger protection would require demonstrated stability, bioavailability, manufacturability, or patient-use benefits that are not predictable from routine formulation practice.

What is the Orange Book status of Temodar?

Temodar is an FDA-approved small-molecule product, and its regulatory framework is the ANDA pathway rather than the biosimilar pathway. FDA’s Orange Book identifies therapeutic-equivalence information and patent or exclusivity records for approved products. [4]

Generic temozolomide products have entered the U.S. market in capsule and injectable presentations. The practical market question is therefore not whether generic entry is legally possible. It is whether a new applicant can obtain approval with sufficient manufacturing reliability and compete against established generic suppliers.

Paragraph IV challenges and litigation

A Paragraph IV certification is relevant when an ANDA applicant asserts that a listed patent is invalid, unenforceable, or will not be infringed. Because the core temozolomide patent has expired, current applicants are more likely to rely on Paragraph III certifications, absence of blocking listed patents, or ordinary ANDA pathways rather than litigating the original compound patent.

The commercial litigation risk is concentrated in three areas:

• Later-issued formulation or delivery patents.
• Method-of-use patents covering a specific dosing regimen or patient population.
• Manufacturing patents involving stable injectable or specialty dosage forms.

No biosimilar litigation framework applies. Temozolomide is not a biologic, and a competitor does not need to establish biosimilarity under the Public Health Service Act.

When did Temodar lose exclusivity and when can generics launch?

Temodar’s original U.S. exclusivity period has ended. Generic launch is already established for oral capsules and injectable temozolomide.

Exclusivity timeline

Milestone	Timing
Temozolomide compound patent filed	Early 1990s
FDA approval of Temodar capsules	1999
Original small-molecule exclusivity	Expired
Historical compound patent term	Expired
Generic capsule entry	Established
Generic injectable competition	Established in the U.S. market

Generic launch timing now depends on ANDA review, manufacturing readiness, product-specific bioequivalence, supply contracts, and commercial pricing. A later entrant can still obtain market share through a differentiated presentation, lower cost of goods, improved service levels, or hospital contracting.

What commercial opportunities exist for Temodar excipients and formulations?

Lactose-free and gelatin-free capsules

A lactose-free capsule could address institutional procurement requirements and a subset of patient preferences. A hydroxypropyl methylcellulose or pullulan capsule shell could support vegetarian or animal-origin restrictions.

The business case is strongest where the product can retain immediate release, match the reference dissolution profile, and avoid a price premium that exceeds the value perceived by payers and hospitals.

Moisture-resistant packaging

Packaging is a significant part of temozolomide stability strategy. High-barrier aluminum-aluminum blisters, desiccant-enabled bottles, and unit-dose packaging can reduce moisture exposure and improve dispensing control.

A packaging patent may be stronger when it claims a defined combination of:

• Capsule formulation.
• Water-vapor transmission limits.
• Desiccant capacity.
• Storage conditions.
• Stability performance over the labeled shelf life.

Packaging differentiation can also reduce handling errors in oncology pharmacies.

Oral liquid, suspension, and dispersible products

Patients with dysphagia, feeding tubes, or limited ability to swallow capsules create a formulation gap. A liquid or suspension product must address temozolomide’s aqueous instability and provide accurate dosing across treatment cycles.

Potential approaches include:

• Dry powder for reconstitution.
• Acidified suspension.
• Temporarily reconstituted unit-dose sachets.
• Enteral-tube-compatible dispersion.
• Taste-masked multiparticulates.
• Dispersible tablets administered immediately after preparation.

The principal barriers are chemical stability after reconstitution, dose uniformity, microbial control, tube compatibility, and safe handling by caregivers. A dry powder for reconstitution may offer a stronger commercial profile than a ready-to-use aqueous liquid because it limits the time temozolomide spends in a hydrolytic environment.

Pediatric and low-dose products

The available 5 mg capsule provides some dose flexibility, but a liquid or dispersible product could improve administration for pediatric and low-body-weight patients. A product designed for weight-based dosing could use a calibrated oral syringe and defined concentration.

Pediatric development would require careful evaluation of taste masking, dosing accuracy, accidental exposure, and caregiver handling. An excipient that improves palatability but increases degradation would not be commercially viable.

Intravenous ready-to-use products

Temozolomide injection is supplied as a lyophilized product requiring reconstitution. A ready-to-use or ready-to-administer presentation could reduce pharmacy preparation time and occupational exposure.

Commercial opportunities include:

• A prefilled infusion container.
• A dual-chamber reconstitution system.
• A closed-vial transfer device.
• A terminally sterilized presentation, if chemically and technically feasible.
• A low-volume concentrate with validated stability.
• A pharmacy-friendly kit with transfer and administration components.

The principal barrier is temozolomide’s solution stability. A product that remains stable only for a short period may have limited value unless it materially improves preparation safety or workflow.

How strong is the Temodar patent estate for a new excipient product?

The legacy estate is weak as a barrier to ordinary generic entry because the core compound and original exclusivity have expired. A new formulation estate could be moderate to strong if it combines composition, process, and performance claims.

Relative patent strength by opportunity

Opportunity	Patent strength potential	Main vulnerability
Substitute lactose with mannitol or cellulose	Low	Routine formulation modification
Replace gelatin capsule shell	Low to moderate	Predictable substitution
Acidified stable suspension	Moderate to high	Prior-art and obviousness challenges
Dry powder for reconstitution	Moderate	Broad prior art in oncology formulations
Tube-compatible dispersible product	Moderate	Need for unexpected stability or administration benefit
Closed cytotoxic manufacturing process	Moderate	Process detection and enablement
Ready-to-use injectable	Moderate to high	Stability and sterility burden
Novel microenvironmental pH system	High if performance is unexpected	Reproducibility and claim scope
Long-acting temozolomide delivery	High potential	Clinical development and toxicity risk

The best protection strategy would use layered claims:

1. Composition claims covering the excipient ratios and pH environment.
2. Product claims covering moisture, impurity, and dissolution specifications.
3. Process claims covering low-moisture or contained manufacture.
4. Packaging claims covering stability-enhancing configurations.
5. Use claims covering patients unable to swallow or requiring enteral administration.

Which companies are challenging Temodar commercially?

The competitive field includes Merck’s branded Temodar product and generic manufacturers supplying temozolomide capsules and injection. Competition is based on price, availability, strength portfolio, wholesaler access, oncology-distributor relationships, and hospital contracting.

Competitive factors

Factor	Impact on market entry
Six capsule strengths	Requires broad SKU and inventory management
Cytotoxic handling	Favors experienced oncology manufacturers
Low clinical differentiation	Intensifies price competition
Limited patient population	Increases importance of supply reliability
Injectable manufacturing	Raises sterility and stability barriers
Hospital contracts	Rewards consistent delivery and documentation
Specialty pharmacy distribution	Favors established channel relationships

Licensing opportunities are more likely to involve technology or regional commercialization than a license to the original Temodar IP. Attractive counterparties may include generic oncology companies, contract development and manufacturing organizations, hospital-compounding suppliers, and specialty pharmaceutical companies with cytotoxic containment capacity.

What manufacturing and regulatory barriers affect temozolomide excipient opportunities?

FDA approval requires the product to meet applicable quality, bioequivalence, stability, and manufacturing standards. For an oral generic, the principal regulatory burden is pharmaceutical equivalence and bioequivalence. For a new dosage form, the sponsor may need a 505(b)(2) application rather than a conventional ANDA, depending on how the product differs from the reference product. [5]

Key CMC requirements

A commercial program should establish:

• Excipient compatibility with temozolomide.
• Blend uniformity across all strengths.
• Degradation-product control.
• Dissolution equivalence.
• Accelerated and long-term stability.
• Container-closure integrity.
• Cytotoxic containment and cleaning validation.
• Extractables and leachables for advanced packaging.
• Microbial and sterility controls for liquid and injectable products.
• Occupational exposure controls.

Manufacturing IP can create a commercial advantage even when it does not block competitors. A process that reduces degradation, eliminates a wet step, or improves containment can lower rejected batches and cost of goods.

How does Temodar compare with competing oral oncology formulations?

Temozolomide differs from many oral oncology products because its clinical value depends on a relatively simple oral regimen, while its formulation risk is driven by chemical stability and cytotoxic handling.

Attribute	Temozolomide capsules	Typical oral targeted oncology drug
Product type	Immediate-release capsule	Often tablet or capsule
Main formulation risk	Hydrolysis and moisture exposure	Solubility, permeability, polymorphism
Dose flexibility	Multiple strengths	Often fewer strengths
Generic pathway	ANDA	ANDA or 505(b)(2), depending on product
Biosimilar pathway	Not applicable	Not applicable for small molecules
Commercial differentiation	Administration, stability, packaging	Formulation, dosing, combination, delivery
Hospital handling	Cytotoxic containment	Varies by active ingredient
Reformulation opportunity	Suspension, dispersible, injectable	Product-specific

The strongest opportunity is not a cosmetic excipient change. It is a product that reduces administration burden or handling risk while preserving temozolomide’s established clinical performance.

What revenue exposure does Temodar face from generic competition?

Temodar faces mature generic erosion because the compound patent and original regulatory exclusivity have expired. Revenue exposure is concentrated in branded prescriptions that remain in use because of physician familiarity, supply preference, reimbursement conditions, or institutional purchasing practices.

A new entrant should expect:

• Rapid price pressure in standard capsule strengths.
• Narrow gross margins for undifferentiated products.
• Greater pricing resilience for injectable, pediatric, or administration-friendly products.
• Higher value from reliable supply than from minor capsule-color changes.
• Stronger commercial positioning through hospital and specialty-pharmacy contracts.

For investors and licensors, the relevant asset is a differentiated formulation with defensible regulatory positioning, not another conventional capsule containing standard excipients.

Key Takeaways

• Temodar contains temozolomide with anhydrous lactose, colloidal silicon dioxide, sodium starch glycolate, tartaric acid, sodium lauryl sulfate, and conventional capsule-shell excipients.
• Tartaric acid and moisture control are central to the formulation strategy because temozolomide is vulnerable to hydrolysis.
• The original temozolomide patent and regulatory exclusivity have expired.
• Biosimilar risk is irrelevant; competition proceeds through small-molecule generic and, for novel products, 505(b)(2) pathways.
• Undifferentiated capsules face heavy price competition.
• The most attractive opportunities are lactose-free or gelatin-free capsules, dry powders for reconstitution, enteral-tube-compatible products, pediatric dosage forms, and ready-to-use injectable systems.
• Stronger patent positions will require demonstrated stability, dosing, handling, or manufacturing advantages.
• Closed cytotoxic processing and moisture-protective packaging can create commercial value even when they do not independently block generic entry.

FAQs About Temodar Excipients and Formulation Strategy

Can temozolomide be formulated without lactose?

Yes. A lactose-free formulation can use alternative diluents such as mannitol, microcrystalline cellulose, or other qualified excipients, but the applicant must demonstrate equivalent performance, stability, and bioequivalence.

Is tartaric acid essential in every temozolomide formulation?

No. Tartaric acid is used in the Temodar capsule formulation, but another acidifying system could be selected if it provides acceptable stability, compatibility, dissolution, and regulatory performance.

Can temozolomide be made into an oral suspension?

Yes, but aqueous stability, dose uniformity, taste, microbial control, and safe cytotoxic handling are major development requirements. A dry powder for reconstitution may provide a more practical stability profile.

Would a vegetarian capsule create patent protection for a generic temozolomide product?

Usually not by itself. Replacing gelatin with a plant-derived capsule shell is generally a predictable formulation modification. Patent strength would improve only if the capsule system produced an unexpected stability, dissolution, or manufacturing benefit.

What is the best commercial formulation opportunity for temozolomide?

A stable, patient-friendly product that solves a recognized administration or handling problem has the strongest opportunity. Dry powder for reconstitution, enteral administration, pediatric dosing, and pharmacy-safe injectable presentations are more commercially defensible than a conventional capsule reformulation.

References

1. Merck Sharp & Dohme LLC. (2024). Temodar (temozolomide) capsules and injection: U.S. prescribing information. U.S. Food and Drug Administration.
2. U.S. Patent No. 5,260,291. (1993). Imidazotetrazine derivatives. U.S. Patent and Trademark Office.
3. U.S. Food and Drug Administration. (1999). FDA approves Temodar for newly diagnosed glioblastoma. FDA oncology product information.
4. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (2017). Applications covered by section 505(b)(2). FDA guidance and regulatory information.